Celularity, Inc. (NASDAQ:CELU) Stock Short Interest Drops 52.3%

Celularity, Inc. (NASDAQ:CELU) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 391,276 shares, a decline of 52.3% from the September 15th total of 821,020 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average daily volume of 154,929 shares, the short-interest ratio is currently 2.5 days.

Institutional Trading of Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in shares of Celularity, Inc. (NASDAQ:CELU) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity accounts for about 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned approximately 2.64% of Celularity as of its most recent SEC filing. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Celularity presently has an average rating of “Sell”.

Celularity Price Performance

Shares of NASDAQ CELU traded down $0.07 on Friday, hitting $1.26. The company’s stock had a trading volume of 5,952 shares, compared to its average volume of 1,349,961. Celularity has a 12-month low of $0.56 and a 12-month high of $2.55. The company has a market capitalization of $40.92 million, a price-to-earnings ratio of -0.46 and a beta of 0.77. The stock has a 50 day moving average of $1.28 and a 200-day moving average of $1.03.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Tuesday, September 29th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $3.85 million for the quarter.

Celularity Company Profile

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.